Zobrazeno 1 - 10
of 459
pro vyhledávání: '"Collins Am"'
Autor:
Singleton WG, Collins AM, Bienemann AS, Killick-Cole CL, Haynes HR, Asby DJ, Butts CP, Wyatt MJ, Barua NU, Gill SS
Publikováno v:
International Journal of Nanomedicine, Vol Volume 12, Pp 1385-1399 (2017)
WG Singleton,1,2 AM Collins,3 AS Bienemann,1 CL Killick-Cole,1 HR Haynes,4 DJ Asby,1 CP Butts,5 MJ Wyatt,1 NU Barua,1,2 SS Gill1,2 1Functional Neurosurgery Research Group, School of Clinical Sciences, University of Bristol, 2Department of Neurosurger
Externí odkaz:
https://doaj.org/article/aab501023622452a81f2d895f5be6579
Publikováno v:
International Journal of Nanomedicine, Vol 2014, Iss Issue 1, Pp 4145-4152 (2014)
Natalie J Wood,1–3 Sarah E Maddocks,4 Helena J Grady,1,2 Andrew M Collins,2 Michele E Barbour11Oral Nanoscience, School of Oral and Dental Sciences, 2Bristol Centre for Functional Nanomaterials, 3Centre for Organised Matter Chemistry, School of Che
Externí odkaz:
https://doaj.org/article/b4123262cca34b9f8d5d865f38ce929b
Publikováno v:
International Journal of Nanomedicine, Vol 2013, Iss default, Pp 3507-3519 (2013)
Michele E Barbour,1 Sarah E Maddocks,2 Natalie J Wood,1,3 Andrew M Collins3 1Oral Nanoscience, School of Oral and Dental Sciences, University of Bristol, Bristol, UK; 2Cardiff School of Health Sciences, Cardiff Metropolitan University, Cardiff, UK; 3
Externí odkaz:
https://doaj.org/article/7b945d6ca68341eea8320c1eefec7531
Autor:
Stuart, ASV, Shaw, RH, Liu, X, Greenland, M, Aley, PK, Andrews, NJ, Cameron, JC, Charlton, S, Clutterbuck, EA, Collins, AM, Darton, T, Dinesh, T, Duncan, CJA, England, A, Faust, SN, Ferreira, DM, Finn, A, Goodman, AL, Green, CA, Hallis, B, Heath, PT, Hill, H, Horsington, BM, Lambe, T, Lazarus, R, Libri, V, Lillie, PJ, Mujadidi, YF, Payne, R, Plested, EL, Provstgaard-Morys, S, Ramasamy, MN, Ramsay, M, Read, RC, Robinson, H, Screaton, GR, Singh, N, Turner, DPJ, Turner, PJ, Vichos, I, White, R, Nguyen-Van-Tam, JS, Snape, MD, Com-COV2 Study Group
Publikováno v:
Lancet (London, England)
Snape, M D 2022, ' Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2) : a single-blind, randomised, phase 2, non-inferiority trial ', Lancet, vol. 399, no. 10319, pp. 36-49 . https://doi.org/10.1016/S0140-6736(21)02718-5
Snape, M D 2022, ' Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2) : a single-blind, randomised, phase 2, non-inferiority trial ', Lancet, vol. 399, no. 10319, pp. 36-49 . https://doi.org/10.1016/S0140-6736(21)02718-5
Background Given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment, we studied mixed priming schedules incorporating an adenoviral-vectored vaccine (ChAdOx1 nCoV-19 [ChAd], AstraZene
Autor:
Shaw, RH, Liu, X, Stuart, ASV, Greenland, M, Aley, PK, Andrews, NJ, Cameron, JC, Charlton, S, Clutterbuck, EA, Collins, AM, Dejnirattisai, W, Dinesh, T, Faust, SN, Ferreira, DM, Finn, A, Green, CA, Hallis, B, Heath, PT, Hill, H, Lambe, T, Lazarus, R, Libri, V, Long, F, Mujadidi, YF, Plested, EL, Morey, ER, Provstgaard-Morys, S, Ramasamy, MN, Ramsay, M, Read, RC, Robinson, H, Screaton, GR, Singh, N, Turner, DPJ, Turner, P, Vichos, J, Walker, LL, White, R, Nguyen-Van-Tam, JS, Snape, MD, Com-COV Study Group
Background: Priming COVID-19 vaccine schedules have been deployed at variable intervals globally, which may influence immune persistence and the relative importance of third-dose ‘booster’ programmes. Here, we report on the impact of 4- versus 12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1032::8f66cb109597a51f09db4bdb89875e25
http://hdl.handle.net/10044/1/96621
http://hdl.handle.net/10044/1/96621
Autor:
Swanson, PA, Padilla, M, Hoyland, W, McGlinchey, K, Fields, PA, Bibi, S, Faust, SN, McDermott, AB, Lambe, T, Pollard, AJ, Durham, NM, Kelly, EJ, AstraZeneca/Oxford/VRC Study Group, Adlou, S, Aley, PK, Angus, B, Anslow, R, Baker, P, Bansal, H, Beveridge, A, Bridges-Webb, A, Ching, S, Cicconi, P, Clutterbuck, EA, Collins, AM, Darton, TC, Demissie, T, Dinesh, T, Douglas, AD, Duncan, CJA, Ewer, KJ, Felle, S, Ferreira, DM, Folegatti, PM, Fuskova, M, Gaudinski, M, Gilbert, SC, Goodman, AL, Gordon, I, Green, CA, Harbolick, E, Hayes, S, Hill, AVS, Hill, H, Jenkin, D, Jepson, BM, Kasanyinga, M, Libri, V, Lillie, PJ, McGregor, AC, Minassian, AM, Mujadidi, YF, Novik, L, Payne, R, Pilataxi, F, Plested, E, Provstgaard-Morys, S, Ramasamy, M, Robinson, H, Sanders, K, Smith, A, Snape, MD, Song, R, Sutherland, RK, Thomson, EC, Toshner, M, Turner, DPJ, Voysey, M, Widge, AT, Williams, CJ
AZD1222 (ChAdOx1 nCoV-19), a replication-deficient simian adenovirus-vectored vaccine, has demonstrated safety, efficacy, and immunogenicity against coronavirus disease 2019 (COVID-19) in clinical trials and real-world studies. We characterized CD4+
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::993e6e80c4502ef8c2b6b487068309ee
https://eprints.whiterose.ac.uk/178925/1/scitranslmed.abj7211.pdf
https://eprints.whiterose.ac.uk/178925/1/scitranslmed.abj7211.pdf
Autor:
Feng, S, Phillips, DJ, White, T, Sayal, H, Aley, PK, Bibi, S, Dold, C, Fuskova, M, Gilbert, SC, Hirsch, I, Humphries, HE, Jepson, B, Kelly, EJ, Plested, E, Shoemaker, K, Thomas, KM, Vekemans, J, Villafana, TL, Lambe, T, Pollard, AJ, Voysey, M, Adlou, S, Allen, L, Angus, B, Anslow, R, Asselin, M-C, Baker, N, Baker, P, Barlow, T, Beveridge, A, Bewley, KR, Brown, P, Brunt, E, Buttigieg, KR, Camara, S, Charlton, S, Chiplin, E, Cicconi, P, Clutterbuck, EA, Collins, AM, Coombes, NS, Clemens, SAC, Davison, M, Demissie, T, Dinesh, T, Douglas, AD, Duncan, CJA, Emary, KRW, Ewer, KJ, Felle, S, Ferreira, DM, Finn, A, Folegatti, PM, Fothergill, R, Fraser, S, Garlant, H, Gatcombe, L, Godwin, KJ, Goodman, AL, Green, CA, Hallis, B, Hart, TC, Heath, PT, Hill, H, Hill, AVS, Jenkin, D, Kasanyinga, M, Kerridge, S, Knight, C, Leung, S, Libri, V, Lillie, PJ, Marinou, S, McGlashan, J, McGregor, AC, McInroy, L, Minassian, AM, Mujadidi, YF, Penn, EJ, Petropoulos, CJ, Pollock, KM, Proud, PC, Provstgaard-Morys, S, Rajapaska, D, Ramasamy, MN, Sanders, K, Shaik, I, Singh, N, Smith, A, Snape, MD, Song, R, Shrestha, S, Sutherland, RK, Thomson, EC, Turner, DPJ, Webb-Bridges, A, Wrin, T, Williams, CJ
Publikováno v:
Nature Medicine
The global supply of COVID-19 vaccines remains limited. An understanding of the immune response that is predictive of protection could facilitate rapid licensure of new vaccines. Data from a randomized efficacy trial of the ChAdOx1 nCoV-19 (AZD1222)
Autor:
Willy Le Roi Togna Pabo, Aurelie Minelle Kengni Ngueko, Alex Durand Nka, Maria Mercedes Santoro, Yagai Bouba, Collins Ambe Chenwi, Ezéchiel Ngoufack Jagni Semengue, Désiré Takou, Georges Teto, Beatrice Dambaya, Raymond Babila Nyasa, Michel Carlos Tommo Tchouaket, Grace Angong Beloumou, Sandrine Claire Djupsa Ndjeyep, Aude Christelle Ka’e, Tatiana Anim Keng Tekoh, Derrick Tambe Ayuk Ngwese, Naomi-Karell Etame, Rachel Audrey Nayang Mundo, Rachel Simo Kamgaing, Samuel Martin Sosso, Roland Ndip Ndip, Vittorio Colizzi, Francesca Cecchereni-Silberstein, Alexis Ndjolo, Joseph Fokam
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
BackgroundThe elevated rate of AIDS-related mortality in Sub-Saharan Africa among adolescents living with HIV (ALHIV) is influenced by various factors, notably immunosuppression, within a framework of limited therapeutic alternatives. We aimed to enh
Externí odkaz:
https://doaj.org/article/3e8845f58da848a9b5fc21d474697fcf
Autor:
Nicholas Tendongfor, Joseph Fokam, Collins Ambe Chenwi, Fabrice Léo Tamhouo Nwabo, Armanda Nangmo, Njume Debimeh, Suzie Tetang Ndiang Moyo, Marie Patrice Halle, Anne-Esther Njom-Nlend, Paul Koki Ndombo, Alexis Ndjolo
Publikováno v:
AIDS Research and Therapy, Vol 20, Iss 1, Pp 1-9 (2023)
Abstract Background In spite of the global decreasing mortality associated with HIV, adolescents living with HIV (ADLHIV) in sub-Saharan Africa still experience about 50% mortality rate. We sought to evaluate survival rates and determinants of mortal
Externí odkaz:
https://doaj.org/article/c6020c852a224985a5611537b6d41927
Autor:
Aude Christelle Ka'e, Maria Mercedes Santoro, Leonardo Duca, Collins Ambe Chenwi, Ezechiel Ngoufack Jagni Semengue, Alex Durand Nka, Naomi-Karell Etame, Willy Leroi Togna Pabo, Grace Beloumou, Marie Laure Mpouel, Sandrine Djupsa, Desire Takou, Samuel Martin Sosso, Hyppolite K. Tchidjou, Vittorio Colizzi, Gregory-Edie Halle-Ekane, Carlo-Federico Perno, Sharon Lewin, R Brad Jones, Caroline T. Tiemessen, Francesca Ceccherini-Silberstein, Joseph Fokam
Publikováno v:
Journal of Virus Eradication, Vol 10, Iss 1, Pp 100367- (2024)
Background: With the advent of antiretroviral therapy (ART), most children living with HIV in sub-Saharan Africa (SSA) are growing toward adolescence, with scarcity of evidence on the size of viral reservoirs to enhance paediatric cure research strat
Externí odkaz:
https://doaj.org/article/3618feb39a9c4458986c039306a9b8f7